- Home
- NTIP vs DARE Comparison
NTIP vs DARE Comparison
Compare NTIP & DARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTIP
- DARE
- Stock Information
- Founded
- NTIP 1990
- DARE 2015
- Country
- NTIP United States
- DARE United States
- Employees
- NTIP N/A
- DARE N/A
- Industry
- NTIP Multi-Sector Companies
- DARE Biotechnology: Pharmaceutical Preparations
- Sector
- NTIP Miscellaneous
- DARE Health Care
- Exchange
- NTIP Nasdaq
- DARE Nasdaq
- Market Cap
- NTIP 28.6M
- DARE 26.3M
- IPO Year
- NTIP 1998
- DARE N/A
- Fundamental
- Price
- NTIP $1.31
- DARE $2.72
- Analyst Decision
- NTIP
- DARE Strong Buy
- Analyst Count
- NTIP 0
- DARE 3
- Target Price
- NTIP N/A
- DARE $12.50
- AVG Volume (30 Days)
- NTIP 26.5K
- DARE 4.3M
- Earning Date
- NTIP 08-11-2025
- DARE 08-11-2025
- Dividend Yield
- NTIP 7.66%
- DARE N/A
- EPS Growth
- NTIP N/A
- DARE N/A
- EPS
- NTIP N/A
- DARE N/A
- Revenue
- NTIP $250,000.00
- DARE $25,909.00
- Revenue This Year
- NTIP N/A
- DARE $99,756.91
- Revenue Next Year
- NTIP N/A
- DARE $119.77
- P/E Ratio
- NTIP N/A
- DARE N/A
- Revenue Growth
- NTIP N/A
- DARE N/A
- 52 Week Low
- NTIP $1.16
- DARE $2.11
- 52 Week High
- NTIP $1.78
- DARE $9.19
- Technical
- Relative Strength Index (RSI)
- NTIP 58.05
- DARE 49.09
- Support Level
- NTIP $1.27
- DARE $2.11
- Resistance Level
- NTIP $1.42
- DARE $9.19
- Average True Range (ATR)
- NTIP 0.06
- DARE 0.59
- MACD
- NTIP 0.01
- DARE 0.05
- Stochastic Oscillator
- NTIP 58.27
- DARE 7.77
About NTIP Network-1 Technologies Inc.
Network-1 Technologies Inc is involved in the business of the development, licensing, and protection of intellectual property assets. The company's current plan includes continuing to pursue licensing opportunities for its intellectual property assets.
About DARE Dare Bioscience Inc.
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.